SCHEMBL3813745

SCHEMBL3813745

CC(C)(C)OC(=O)NCCNc1nc(Cl)ccc1[N+](=O)[O-]

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
HTT P42858 2/20 0.47
STK17B O94768 1/20 0.47
STK17A Q9UEE5 1/20 0.47
BCHE P06276 1/20 0.45
LATS1 O95835 1/20 0.44
BRD4 O60885 6/20 0.44
MALT1 Q9UDY8 1/20 0.41
IDO1 P14902 1/20 0.40
FGFR4 P22455 1/20 0.39
LMNA P02545 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3815684 0.93 STK17B (0.56) MAPTHTTSTK17BSTK17ABRD4
SCHEMBL3812414 0.90 MAPT (0.44) MAPTSTK17BSTK17ABCHELATS1
SCHEMBL3408429 0.86 TXNRD1 (0.47) MAPTSTK17BSTK17ABCHELATS1
SCHEMBL12968578 0.84 STK17A (0.62) MAPTSTK17BSTK17ABCHELATS1
SCHEMBL906275 0.84 MAPT (0.64) MAPTHTTFGFR4LMNACYP1A2
SCHEMBL1181351 0.82 MAPT (0.48) MAPTSTK17BSTK17ABCHELATS1
SCHEMBL3815554 0.82 LATS1 (0.42) MAPTSTK17BSTK17ABCHELATS1
SCHEMBL4273250 0.81 LMNA (0.60) MAPTSTK17BSTK17ABCHELATS1
SCHEMBL3410303 0.80 STK17B (0.49) STK17BSTK17ABRD4LMNA
SCHEMBL3811501 0.80 LATS1 (0.38) MAPTHTTSTK17BSTK17ABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615925-B1 IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS IPSEN PHARMA (FR) 2009-05-27 EP disclosed
US-7495009-B2 Imidazopyridine derivatives as melancortin receptor agonists SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-02-24 US disclosed
US-20060173036-A1 Imidazopyridine derivatives as melanocortin receptor agonists SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) 2006-08-03 US disclosed
EP-1615925-A1 IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-01-18 EP disclosed
WO-2004089951-A1 IMIDAZOPYRIDINE DERIVATIVES HAVING AN AFFINITY FOR MELANOCORTIN RECEPTORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173036-A1 Imidazopyridine derivatives as melanocortin receptor agonists MC4R, MC1R, MC3R MAPT 2117/4885HTT 1430/4885STK17B 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.